| Name | Title | Contact Details |
|---|---|---|
Ina Shtëmbari |
People and Culture Lead (HR Director, R&D) | Profile |
James Cronin |
Sr Director - R&D Development IT | Profile |
Jimmy Salcedo |
Executive Director, R&D Portfolio Management and Operations | Profile |
Michael Belcourt |
Senior Director, Global R&D Strategy, Portfolio & Project Management at Alexion Pharmaceuticals | Profile |
Andrew Bowler |
Associate Director, Global Strategic Sourcing R&D | Profile |
Gen9 is the premier next-generation gene synthesis company focused on high-quality, high-throughput, automated production of DNA constructs. The Gen9 technology allows for the lowest-cost and highest-quality DNA constructs commercially available. Founded by world leaders in synthetic biology, Gen9 aims to ensure the constructive application of synthetic biology in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels. Gen9 is powering the synthetic biology revolution from our headquarters in Cambridge, Mass
TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics.
We are committed to helping people with severe, chronic cardiovascular diseases realize the promise of patient-specific, expanded multicellular therapy.
Autem Therapeutics is a privately held oncology therapeutic and bioelectric company headquartered in Hanover NH, USA that is developing a novel, non-invasive and non-toxic oncology treatment platform targeting HCC (liver cancer) and other solid tumor cancers.
Tri-Source Pharma is a pharmaceutical manufacturer/distributor operating in both the human and animal health care industries.